1. Feely J, Isles TE. Screening for thyroid dysfunction in diabetics. British Medical Journal. 1979;1(6179):p. 1678. [PMC free article] [PubMed] [Google Scholar]
2. Gray RS, Irvine WJ, Clarke BF. Screening for thyroid dysfunction in diabetics. British medical journal. 1979;2(6202):p. 1439. [PMC free article] [PubMed] [Google Scholar]
3. Tunbridge WMG, Evered DC, Hall R. The spectrum of thyroid disease in a community: the Whickham survey. Clinical Endocrinology. 1977;7(6):481–493. [PubMed] [Google Scholar]
4. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The colorado thyroid disease prevalence study. Archives of Internal Medicine. 2000;160(4):526–534. [PubMed] [Google Scholar]
5. Hollowell JG, Staehling NW, Dana Flanders W, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) Journal of Clinical Endocrinology and Metabolism. 2002;87(2):489–499. [PubMed] [Google Scholar]
6. Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabetic Medicine. 1995;12(7):622–627. [PubMed] [Google Scholar]
7. Papazafiropoulou A. Prevalence of thyroid dysfunction among greek Type 2 diabetic patients attending an outpatient clinic. Journal of Clinical Medicine Research. 2010;2(2):75–78. [PMC free article] [PubMed] [Google Scholar]
8. Akbar DH, Ahmed MM, Al-Mughales J. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. Acta Diabetologica. 2006;43(1):14–18. [PubMed] [Google Scholar]
9. Radaideh ARM, Nusier MK, Amari FL, et al. Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan. Saudi Medical Journal. 2004;25(8):1046–1050. [PubMed] [Google Scholar]
10. Kordonouri O, Charpentier N, Hartmann R. GADA positivity at onset of type 1 diabetes is a risk factor for the development of autoimmune thyroiditis. Pediatric Diabetes. 2011;12(1):31–33. [PubMed] [Google Scholar]
11. Radetti G, Paganini C, Gentill L, et al. Frequency of Hashimoto’s thyroiditis in children with type 1 diabetes mellitus. Acta Diabetologica. 1995;32(2):121–124. [PubMed] [Google Scholar]
12. Kordonouri O, Deiss D, Danne T, Dorow A, Bassir C, Grüters-Kieslich A. Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes. Diabetic Medicine. 2002;19(6):518–521. [PubMed] [Google Scholar]
13. Kordonouri O, Hartmann R, Deiss D, Wilms M, Grüters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Archives of Disease in Childhood. 2005;90(4):411–414. [PMC free article] [PubMed] [Google Scholar]
14. Lindberg B, Ericsson UB, Ljung R, Ivarsson SA. High prevalence of thyroid autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children. Journal of Laboratory and Clinical Medicine. 1997;130(6):585–589. [PubMed] [Google Scholar]
15. Ghawil M, Tonutti E, Abusrewil S, et al. Autoimmune thyroid disease in Libyan children and young adults with type 1 diabetes mellitus. European Journal of Pediatrics. In press. [PubMed] [Google Scholar]
16. Eisenbarth GS, Gottlieb PA. Medical progress: autoimmune polyendocrine syndromes. New England Journal of Medicine. 2004;350(20):2068–2079. [PubMed] [Google Scholar]
17. Holl RW, Böhm B, Loos U, Grabert M, Heinze E, hom*oki J. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type. Hormone Research. 1999;52(3):113–118. [PubMed] [Google Scholar]
18. Santamaria P, Barbosa JJ, Lindstrom AL, Lemke TA, Goetz FC, Rich SS. HLA-DQB1-associated susceptibility that distinguishes Hashimoto’s thyroiditis from Graves’ disease in type I diabetic patients. Journal of Clinical Endocrinology and Metabolism. 1994;78(4):878–883. [PubMed] [Google Scholar]
19. Kim EY, Shin CH, Yang SW. Polymorphisms of HLA class II predispose children and adolescents with type 1 diabetes mellitus to autoimmune thyroid disease. Autoimmunity. 2003;36(3):177–181. [PubMed] [Google Scholar]
20. Levin L, Ban Y, Concepcion E, Davies TF, Greenberg DA, Tomer Y. Analysis of HLA genes in families with autoimmune diabetes and thyroiditis. Human Immunology. 2004;65(6):640–647. [PubMed] [Google Scholar]
21. Dittmar M, Ide M, Wurm M, Kahaly GJ. Early onset of polyglandular failure is associated with HLA-DRB1∗03. European Journal of Endocrinology. 2008;159(1):55–60. [PubMed] [Google Scholar]
22. Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. Journal of Clinical Endocrinology and Metabolism. 2005;90(8):4904–4911. [PMC free article] [PubMed] [Google Scholar]
23. Ikegami H, Awata T, Kawasaki E, et al. The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):1087–1092. [PubMed] [Google Scholar]
24. Dultz G, Matheis N, Dittmar M, Röhrig B, Bender K, Kahaly GJ. The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes. Thyroid. 2009;19(2):143–148. [PubMed] [Google Scholar]
25. Kawasaki E, Awata T, Ikegami H, et al. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. American Journal of Medical Genetics. 2006;140(6):586–593. [PubMed] [Google Scholar]
26. Villano MJB, Huber AK, Greenberg DA, Golden BK, Concepcion E, Tomer Y. Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohort of multiplex families. Journal of Clinical Endocrinology and Metabolism. 2009;94(4):1458–1466. [PMC free article] [PubMed] [Google Scholar]
27. Maxon HR, Kreines KW, Goldsmith RE, Knowles HC. Long-term observations of glucose tolerance in thyrotoxic patients. Archives of Internal Medicine. 1975;135(11):1477–1480. [PubMed] [Google Scholar]
28. O’Meara NM, Blackman JD, Sturis J, Polonsky KS. Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism. 1993;76(1):79–84. [PubMed] [Google Scholar]
29. Dimitriadis G, Baker B, Marsh H, et al. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. The American journal of physiology. 1985;248(5):E593–E601. [PubMed] [Google Scholar]
30. Bech K, Damsbo P, Eldrup E, et al. β-Cell function and glucose and lipid oxidation in Graves’ disease. Clinical Endocrinology. 1996;44(1):59–66. [PubMed] [Google Scholar]
31. Beer SF, Parr JH, Temple RC, Hales CN. The effect of thyroid disease on proinsulin and C-peptide levels. Clinical Endocrinology. 1989;30(4):379–383. [PubMed] [Google Scholar]
32. Levin RJ, Smyth DH. The effect of the thyroid gland on intestinal absorption of hexoses. The Journal of physiology. 1963;169:755–769. [PMC free article] [PubMed] [Google Scholar]
33. Matty AJ, Seshadri B. Effect of thyroxine on the isolated rat intestine. Gut. 1965;6:200–202. [PMC free article] [PubMed] [Google Scholar]
34. Kemp HF, Hundal HS, Taylor PM. Glucose transport correlates with GLUT2 abundance in rat liver during altered thyroid status. Molecular and Cellular Endocrinology. 1997;128(1-2):97–102. [PubMed] [Google Scholar]
35. Mokuno T, Uchimura K, Hayashi R, et al. Glucose transporter 2 concentrations in hyper- and hypothyroid rat livers. Journal of Endocrinology. 1999;160(2):285–289. [PubMed] [Google Scholar]
36. Vaughan M. An in vitro effect of triiodothyronine on rat adipose tissue. Journal of Clinical Investigation. 1967;46(9):1482–1491. [PMC free article] [PubMed] [Google Scholar]
37. Miki N, Ono M, Hizuka N, Aoki T, Demura H. Thyroid hormone modulation of the hypothalamic growth hormone (GH)- releasing factor-pituitary GH axis in the rat. Journal of Clinical Investigation. 1992;90(1):113–120. [PMC free article] [PubMed] [Google Scholar]
38. Tosi F, Moghetti P, Castello R, Negri C, Bonora E, Muggeo M. Early changes in plasma glucagon and growth hormone response to oral glucose in experimental hyperthyroidism. Metabolism. 1996;45(8):1029–1033. [PubMed] [Google Scholar]
39. Sestoft L, Christensen NJ, Saltin B. Responses of glucose and glucoregulatory hormones to exercise in thyrotoxic and myxoedematous patients before and after 3 months of treatment. Clinical Science. 1991;81(1):91–99. [PubMed] [Google Scholar]
40. Solá E, Morillas C, Garzón S, Gómez-Balaguer M, Hernández-Mijares A. Association between diabetic ketoacidosis and thyrotoxicosis. Acta Diabetologica. 2002;39(4):235–237. [PubMed] [Google Scholar]
41. Bhattacharyya A, Wiles PG. Diabetic ketoacidosis precipitated by thyrotoxicosis. Postgraduate Medical Journal. 1999;75(883):291–292. [PMC free article] [PubMed] [Google Scholar]
42. Okajima F, Ui M. Metabolism of glucose in hyper- and hypo-thyroid rats in vivo. Glucose-turnover values and futile-cycle activities obtained with 14C- and 3H-labelled glucose. Biochemical Journal. 1979;182(2):565–575. [PMC free article] [PubMed] [Google Scholar]
43. Leong KS, Wallymahmed M, Wilding J, MacFarlane I. Clinical presentation of thyroid dysfunction and Addison’s disease in young adults with type 1 diabetes. Postgraduate Medical Journal. 1999;75(886):467–470. [PMC free article] [PubMed] [Google Scholar]
44. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin action in adipose tissue and muscle in hypothyroidism. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4930–4937. [PubMed] [Google Scholar]
45. Cettour-Rose P, Theander-Carrillo C, Asensio C, et al. Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion. Diabetologia. 2005;48(4):624–633. [PubMed] [Google Scholar]
46. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. European Journal of Endocrinology. 2009;160(5):785–790. [PubMed] [Google Scholar]
47. Rochon C, Tauveron I, Dejax C, et al. Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism. Clinical Science. 2003;104(1):7–15. [PubMed] [Google Scholar]
48. Dimitriadis G, Parry-Billings M, Bevan S, et al. The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats. European Journal of Clinical Investigation. 1997;27(6):475–483. [PubMed] [Google Scholar]
49. Lai Y, Wang J, Jiang F, et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocrine Journal. 2011;58(1):23–30. [PubMed] [Google Scholar]
50. Erdogan M, et al. Metabolic syndrome prevelance in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters. Journal of Endocrinological Investigation. In press. [PubMed] [Google Scholar]
51. Chen HS, Wu TEJ, Jap TS, et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabetic Medicine. 2007;24(12):1336–1344. [PubMed] [Google Scholar]
52. Singer MA. Of mice and men and elephants: metabolic rate sets glomerular filtration rate. American Journal of Kidney Diseases. 2001;37(1):164–178. [PubMed] [Google Scholar]
53. Den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clinical Endocrinology. 2005;62(4):423–427. [PubMed] [Google Scholar]
54. Yang GR, Yang JK, Zhang L, An YH, Lu JK. Association between subclinical hypothyroidism and proliferative diabetic retinopathy in type 2 diabetic patients: a case-control study. Tohoku Journal of Experimental Medicine. 2010;222(4):303–310. [PubMed] [Google Scholar]
55. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE. Brain adipocytokine action and metabolic regulation. Diabetes. 2006;55(2):S145–S154. [PubMed] [Google Scholar]
56. Fernández-Real JM, López-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. Journal of Clinical Endocrinology and Metabolism. 2003;88(6):2714–2718. [PubMed] [Google Scholar]
57. Cabanelas A, Cordeiro A, Santos Almeida NAD, et al. Effect of triiodothyronine on adiponectin expression and leptin release by white adipose tissue of normal rats. Hormone and Metabolic Research. 2010;42(4):254–260. [PubMed] [Google Scholar]
58. Yaturu S, Prado S, Grimes SR. Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. Journal of Cellular Biochemistry. 2004;93(3):491–496. [PubMed] [Google Scholar]
59. Saito T, Kawano T, Saito T, et al. Elevation of serum adiponectin levels in Basedow disease. Metabolism. 2005;54(11):1461–1466. [PubMed] [Google Scholar]
60. Yu H, Yang Y, Zhang M, et al. Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects. Nutrition and Metabolism. 2006;3, article no. 13 [PMC free article] [PubMed] [Google Scholar]
61. Iglesias P, Alvarez Fidalgo P, Codoceo R, Díez JJ. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clinical Endocrinology. 2003;59(5):621–629. [PubMed] [Google Scholar]
62. Altinova AE, Törüner FB, Aktürk M, et al. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clinical Endocrinology. 2006;65(4):530–535. [PubMed] [Google Scholar]
63. Nagasaki T, Inaba M, Hiura Y, et al. Plasma levels of adiponectin and soluble thrombomodulin in hypothyroid patients with normal thyroid function following levothyroxine replacement therapy. Biomedicine and Pharmacotherapy. 2005;59(10):571–577. [PubMed] [Google Scholar]
64. Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clinical Endocrinology. 1998;49(5):583–588. [PubMed] [Google Scholar]
65. Valcavi R, Zini M, Peino R, Casanueva FF, Dieguez C. Influence of thyroid status on serum immunoreactive leptin levels. Journal of Clinical Endocrinology and Metabolism. 1997;82(5):1632–1634. [PubMed] [Google Scholar]
66. Corbetta S, Englaro P, Giambona S, Persani L, Blum WF, Beck-Peccoz P. Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. European Journal of Endocrinology. 1997;137(6):659–663. [PubMed] [Google Scholar]
67. Leonhardt U, Ritzel U, Schäfer G, Becker W, Ramadori G. Serum leptin levels in hypo- and hyperthyroidism. Journal of Endocrinology. 1998;157(1):75–79. [PubMed] [Google Scholar]
68. Mazaki-Tovi M, Feuermann Y, Segev G, et al. Increased serum leptin and insulin concentrations in canine hypothyroidism. Veterinary Journal. 2010;183(1):109–114. [PubMed] [Google Scholar]
69. Jílková ZM, Pavelka S, Flachs P, Hensler M, Kůs V, Kopecký J. Modulation of type I iodothyronine 5’-deiodinase activity in white adipose tissue by nutrition: possible involvement of leptin. Physiological Research. 2010;59(4):561–569. [PubMed] [Google Scholar]
70. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Archives of Surgery. 2003;138(4):389–396. [PubMed] [Google Scholar]
71. Flanagan DE, Evans ML, Monsod TP, et al. The influence of insulin on circulating ghrelin. American Journal of Physiology. 2003;284(2 47-2):E313–E316. [PubMed] [Google Scholar]
72. Altinova AE, Törüner FB, Aktürk M, et al. Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Hormone Research. 2006;65(6):295–299. [PubMed] [Google Scholar]
73. Riis ALD, Hansen TK, Møller N, Weeke J, Jørgensen JOL. Hyperthyroidism is associated with suppressed circulating ghrelin levels. Journal of Clinical Endocrinology and Metabolism. 2003;88(2):853–857. [PubMed] [Google Scholar]
74. Brąclik M, Marcisz C, Giebel S, Orzeł A. Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction. Thyroid. 2008;18(5):545–550. [PubMed] [Google Scholar]
75. Theodoropoulou A, Psyrogiannis A, Metallinos IC, Habeos I, Vgenakis AG, Kyriazopoulou V. Ghrelin response to oral glucose load in hyperthyroidism, before and after treatment with antithyroid drugs. Journal of Endocrinological Investigation. 2009;32(2):94–97. [PubMed] [Google Scholar]
76. Röjdmark S, Calissendorff J, Danielsson O, Brismar K. Hunger-satiety signals in patients with graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine. 2005;27(1):55–61. [PubMed] [Google Scholar]
77. Giménez-Palop O, Giménez-Pérez G, Mauricio D, et al. Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. European Journal of Endocrinology. 2005;153(1):73–79. [PubMed] [Google Scholar]
78. Saad MF, Bernaba B, Hwu CM, et al. Insulin regulates plasma ghrelin concentration. Journal of Clinical Endocrinology and Metabolism. 2002;87(8):3997–4000. [PubMed] [Google Scholar]
79. Gjedde S, Vestergaard ET, Gormsen LC, et al. Serum ghrelin levels are increased in hypothyroid patients and become normalized by L-thyroxine treatment. Journal of Clinical Endocrinology and Metabolism. 2008;93(6):2277–2280. [PubMed] [Google Scholar]
80. Caminos JE, Seoane LM, Tovar SA, Casanueva FF, Dieguez C. Influence of thyroid status and growth hormone deficiency on ghrelin. European Journal of Endocrinology. 2002;147(1):159–163. [PubMed] [Google Scholar]
81. Sadegholvad A, Afkhamizadeh M, Ranjbar-Omrani G. Serum Ghrelin changes in thyroid dysfunction. Archives of Iranian Medicine. 2007;10(2):168–170. [PubMed] [Google Scholar]
82. Tanda ML, Lombardi V, Genovesi M, et al. Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction. Journal of Endocrinological Investigation. 2009;32(1):74–78. [PubMed] [Google Scholar]
83. Lanni A, Moreno M, Lombardi A, Goglia F. Thyroid hormone and uncoupling proteins. FEBS Letters. 2003;543(1–3):5–10. [PubMed] [Google Scholar]
84. Harris M, Aschkenasi C, Elias CF, et al. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. Journal of Clinical Investigation. 2001;107(1):111–120. [PMC free article] [PubMed] [Google Scholar]
85. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. Journal of Clinical Investigation. 2000;106(2):253–262. [PMC free article] [PubMed] [Google Scholar]
86. Decherf S, Seugnet I, Kouidhi S, Lopez-Juarez A, Clerget-Froidevaux MS, Demeneix BA. Thyroid hormone exerts negative feedback on hypothalamic type 4 melanocortin receptor expression. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(9):4471–4476. [PMC free article] [PubMed] [Google Scholar]
87. Claret M, Smith MA, Batterham RL, et al. AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. Journal of Clinical Investigation. 2007;117(8):2325–2336. [PMC free article] [PubMed] [Google Scholar]
88. López M, Varela L, Vázquez MJ, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nature Medicine. 2010;16(9):1001–1008. [PMC free article] [PubMed] [Google Scholar]
89. Gursoy NT, Tuncel E. The relationship between the glycemic control and the hypothalamus-pituitary-thyroid axis in diabetic patients. Turkish Journal of Endocrinology and Metabolism. 1999;(4):163–168. [Google Scholar]
90. Coiro V, Volpi R, Marchesi C, et al. Influence of residual C-peptide secretion on nocturnal serum TSH peak in well-controlled diabetic patients. Clinical Endocrinology. 1997;47(3):305–310. [PubMed] [Google Scholar]
91. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid. 2008;18(4):461–464. [PubMed] [Google Scholar]
92. Ayturk S, Gursoy A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. European Journal of Endocrinology. 2009;161(4):599–605. [PubMed] [Google Scholar]
93. Kalmann R, Mourits MP. Diabetes mellitus: a risk factor in patients with Graves’ orbitopathy. British Journal of Ophthalmology. 1999;83(4):463–465. [PMC free article] [PubMed] [Google Scholar]
